Sorry about the new thread, had trouble finding the last one, at work with no time!Lifeline Biotechnologies Explores Breast Cancer False Positives versus True Benigns
Wednesday April 14, 9:01 am ET
VIENNA, Austria--(BUSINESS WIRE)--April 14, 2004--Jim Holmes, CEO Lifeline Biotechnologies (OTC:LBTT - News) today announced that as a result of a meeting recently held with Professor Max Moser the Company expects to retain the Joanneum Research Institute of Graz, Austria and its team of Chrono Rhythm experts to assist in the definition of true false positives and true benign lesions.
Dr. Reeves, Lifeline's President, as a result of his many years of research, believes that false positives detected in earlier clinical trials, conducted by Lifeline, are not all false positives. His position is that within the false positives are some early breast cancers. Further research is being undertaken to differentiate true false positives from potential breast cancers.
A further outcome of the recent meeting with Professor Moser resulted in Lifeline receiving an invitation to present various aspects of its First Warning(TM) Early Breast Cancer Detection Technology at the First International Conference on Cancer and Rhythm to be held October 14 through 16, 2004, at the University of Graz, Austria.
Professor Moser commented that the Conference is being sponsored by the Joanneum Research Institute, The Medical University of Graz and The Allgemeine Unfallversicherungsanstalt, Vienna. The Organizing Committee has invited 21 of the World's leading authorities to discuss mounting recent evidence that disturbances of circadian rhythms significantly contribute to the development of cancer. Circadian rhythms are part of the normal activities of the human body that reflect the organisms well-being.
Among the invited speakers is Professor Louis G. Keith, MD, Ph.D. Lifeline Biotechnologies' Medical Director. Dr. Keith's invited topic will be "Circadian Rhythm Chaos -- a New Cancer Marker." Dr. Keith will be presenting empirical and clinical evidence that circadian rhythm chaos is the most important marker that we have today to indicate the presence of breast cancer.
In addition, Dr. William Reeves, President and Founder of Lifeline Biotechnologies, will present a poster (scientific exhibit) entitled "False Positive Interpretations in Breast Cancer Screening." Dr. Reeves states, "Sufficient evidence exists that demonstrates a high probability of a previously undetected form of breast cancer. A certain portion of false positive results eventually prove to be breast cancer. Therefore, an incipient form of breast cancer is likely to exist."
Holmes noted the Conference will bring together important researchers in the fields of chronobiology and chronomedicine to exchange state-of-the-art research results and to address open issues. Because of Lifeline's longstanding interest in chronobiology and breast cancer, the basis of its First Warning(TM) System, Professor Moser believes the Company's presence, as a leader in this technology, is vital to the success of the conference. Holmes and Drs. Keith and Reeves see this as an opportunity to further Lifeline's investigation of false positives with the anticipation of separating true false positives from potential cancers.
Lifeline's website address: www.lbti.com
posted